Evidence for Immunogenicity of Cervarix™ vs Gardasil®
STUDY DETAILS					SUMMARY
Study	Vaccine	Study Design	Participants	Summary of Key Findings	Level of Evidence	Quality
HPV010 (117,136)	Cervarix™ vs Gardasil®	Observer-blind study To compare the immunogenicity of these vaccines 12 months after a third dose (Month 18).	Females 18 to 45 years n=1106	GMTs of serum neutralizing antibodies ranged from 2.3–4.8-fold higher for HPV-16 and 6.8–9.1-fold higher for HPV-18 after vaccination with Cervarix™ compared with Gardasil®, across all age strata. In the TVC, Cervarix™ induced significantly higher serum neutralizing antibody titers in all age strata (p < 0.0001). Incidence of unsolicited adverse events was comparable between vaccinated groups; incidence of solicited symptoms was generally higher after Cervarix™, with injection site reactions being most common.	Level I	Good